The HER2/neu 655 A>G polymorphism has been linked to cardiotoxicity risk. This study evaluates the cost-effectiveness of HER2/neu 655 genotyping. Methods: Eighty-eight HER2-positive breast cancer ...

A study published by Caris showed that certain tumor types had very low or no HER2 overexpression, which has implications for biomarker testing strategies.

Panelists discuss how integrating HER2-directed therapies into existing NSCLC decision-making processes presents challenges, focusing on strategies for timely updates as new therapies emerge and ...

Among previously treated patients with human epidermal growth factor receptor 2 (HER2, ERBB2)–mutant advanced non-small cell lung cancer (NSCLC), zongertinib has received priority review from the Food ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

The conversion to traditional approval was supported by data from the phase 3 KEYNOTE-811 study (ClinicalTrials.gov Identifier: NCT03615326), which included 698 patients with HER2-positive ...

The Food and Drug Administration (FDA) has granted accelerated approval to Ziihera ® (zanidatamab-hrii) for the treatment of adults with previously treated, unresectable or metastatic HER2 ...

One-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast cancer with a poorer prognosis. Investigators of the Vall d'Hebron ...

The HER2 ADC came to Pfizer via its $43 billion acquisition of Seagen, which in-licensed the drug’s ex-Asia rights in 2021 after paying RemeGen $200 million upfront.. However, with AstraZeneca ...

U.S. FDA Accepts New Drug Application Under Priority Review for sevabertinib (BAY 2927088) in HER2-Mutant Non-Small Cell Lung Cancer. Regulatory submission is based on positive results from the ...